Enantioselective analysis of praziquantel and trans-4-hydroxypraziquantel in human plasma by chiral LC-MS/MS: Application to pharmacokinetics

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Oct 1;877(27):3083-8. doi: 10.1016/j.jchromb.2009.07.036. Epub 2009 Aug 3.

Abstract

A simple enantioselective method for the determination of praziquantel (PZQ) and trans-4-hydroxypraziquantel (4-OHPZQ) in human plasma was developed and validated by high-performance liquid chromatography/mass spectrometry. The plasma samples were prepared by liquid-liquid extraction using a mixture of methyl-tert-butylether/dichloromethane (2:1, v/v) as extraction solvent. The direct resolution of PZQ and 4-OHPZQ enantiomers was performed on a Chiralpak AD column using hexane-isopropanol (75:25, v/v) as the mobile phase. Diazepam was used as internal standard. The method described here is simple and reproducible. The quantitation limit of 1.25ng/ml for each PZQ enantiomer and of 12.5ng/ml for each 4-OHPZQ enantiomer permits the use of the method in studies investigating the kinetic disposition of a single dose of 1.5g racemic PZQ. Enantioselectivity in the kinetic disposition of PZQ and 4-OHPZQ was observed in the clinical study, with the demonstration of a higher proportion of the (+)-(S)-PZQ and (-)-(R)-4-OHPZQ enantiomers in plasma.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromatography, Liquid / methods*
  • Humans
  • Linear Models
  • Praziquantel / analogs & derivatives*
  • Praziquantel / blood*
  • Praziquantel / pharmacokinetics
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Stereoisomerism
  • Tandem Mass Spectrometry / methods*

Substances

  • 4-hydroxypraziquantel
  • Praziquantel